Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.64 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | VNN1 | O95497 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16049766 | 0.81 | NAMPT (0.59) | NAMPTGPR119VNN1HDAC1HDAC6 | |
| SCHEMBL3661148 | 0.80 | GPR119 (0.44) | NAMPTGPR119 | |
| SCHEMBL23660646 | 0.80 | NAMPT (0.58) | NAMPTGPR119HDAC1HDAC6OPRD1 | |
| SCHEMBL30017841 | 0.80 | NAMPT (0.58) | NAMPTGPR119HDAC1HDAC6OPRD1 | |
| SCHEMBL2172491 | 0.80 | NAMPT (0.63) | NAMPTGPR119HDAC1HDAC6OPRD1 | |
| SCHEMBL20766101 | 0.80 | HDAC2 (0.51) | HDAC1JAK2JAK1 | |
| SCHEMBL22660467 | 0.79 | NAMPT (0.57) | NAMPTGPR119HDAC1HDAC6OPRD1 | |
| SCHEMBL13398040 | 0.79 | NAMPT (0.60) | NAMPTGPR119CYP2C9 | |
| SCHEMBL25596625 | 0.79 | NAMPT (0.57) | NAMPTGPR119VNN1HDAC1HDAC6 | |
| SCHEMBL22660803 | 0.79 | NAMPT (0.57) | NAMPTGPR119HDAC1HDAC6OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | NAMPT 153/4885GPR119 2567/4885VNN1 443/4885 |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | NAT1, RIF1, MRPL21 | NAMPT 621/4885GPR119 2610/4885VNN1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.